Navigation Links
Researchers uncover key trigger for potent cancer-fighting marine product

An unexpected discovery in marine biomedical laboratories at Scripps Institution of Oceanography at UC San Diego has led to new, key information about the fundamental biological processes inside a marine organism that creates a natural product currently being tested to treat cancer in humans. The finding could lead to new applications of the natural product in treating human diseases.

A research team led by Bradley Moore, a professor with UCSDs Scripps Oceanography Center for Marine Biotechnology and Biomedicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, and postdoctoral researcher Alessandra Eustquio, along with their colleagues at the Salk Institute for Biological Studies, discovered an enzyme called SalL inside Salinispora tropica, a promising marine bacterium identified in 1991 by Scripps researchers.

As they describe in the most recent issue of Nature Chemical Biology, the researchers also identified a novel processa pathwayfor the way the marine bacterium incorporates a chlorine atom, the key ingredient for triggering its potent cancer-fighting natural product. Previously known methods for activating chlorine were processed through oxygen-based approaches. The new method, on the other hand, employs a substitution strategy that uses non-oxidized chlorine as it is found in nature, as with common table salt.

This was a totally unexpected pathway, said Moore. There are well over 2,000 chlorinated natural products and this is the first example in which chlorine is assimilated by this kind of pathway, said Moore.

The Salinispora derivative salinosporamide A is currently in phase I human clinical trials for the treatment of multiple myeloma and other cancers. A team led by Moore and Scripps Daniel Udwary solved the genome of S. tropica in June, an achievement that helped pave the way for the new discoveries.

Moore believes the discoveries provide a new road map for furthering S. tropicas potential for drug development. Knowing the pathway of how the natural product is made biologically may give biotechnology and pharmaceutical scientists the ability to manipulate key molecules to engineer new versions of Salinispora-derived drugs. Genetic engineering may allow the development of second-generation compounds that cant be found in nature.

Its possible that drug companies could manufacture this type of drug in greater quantities now that we know how nature makes it, said Moore.

At this point it is unclear how pervasively SalL and its unique biological activation pathway exist in the ocean environment. Chlorine is a major component of seawater, and, according to Moore, a fundamental component of Salinisporas disease-inhibiting abilities. Salinosporamide A, for example, is 500 times more potent than its chlorine-free analog salinosporamide B.

The chlorine atom in salinosporamide A is key to the drugs irreversible binding to its biological target and one of the reasons the drug is so effective against cancer, said Moore.

According to Eustquio, finding the enzyme and its new pathway also carries implications for understanding evolutionary developments, including clues for how and why related enzymes are activated in different ways.


Contact: Mario Aguilera
University of California - San Diego

Related biology news :

1. Worth a thousand words: Hopkins researchers paint picture of cancer-promoting culprit
2. Novel mechanism for long-term learning identified by Carnegie Mellon researchers
3. Cornell researchers prove how plants transport sugars
4. Researchers discover protein that controls bone growth
5. Dolphin therapy a dangerous fad, Emory researchers warn
6. ASU researchers use NASA satellites to improve pollution modeling
7. OHSU researchers reveal the science of shivering
8. Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema
9. WUSTL researchers spearhead key genome initiative
10. Penn researchers shine the light of venus to learn how the herpes virus invades cells
11. University of Pennsylvania researchers zero in on the tiniest members in the war on cancer
Post Your Comments:
Related Image:
Researchers uncover key trigger for potent cancer-fighting marine product
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology: